• Happy Holidays from AcceGen! Orders placed during Dec 22–Jan 2 will be processed and shipped after operations resume. Please plan ahead.

Tumor Cell Lines

RT-112/84

  • For research use only

Cat No.

ABC-TC0999

Product Type

Human Bladder Cancer Cell Lines

Cell Type

Epithelial

Species

Human

Growth Conditions

37 ℃, 5% CO2

Source Organ

Bladder

Product Code

RT112-84; RT-112/84; RT11284

RT-112/84 Bladder Carcinoma Cells grow slowly and support bladder tumor progression modeling, epithelial biology, and chemotherapy profiling.

Product Image

Description

Phase-contrast of RT-112/84 human bladder transitional cell carcinoma (TCC) cells in adherent monolayer culture.
RT112/84 is a human bladder transitional cell carcinoma (TCC) cell line established in 1973 from a primary tumor of an untreated female patient with bladder cancer. The cells exhibit epithelial-like morphology and adherent growth properties, with a reported doubling time of approximately 23–35 hours. RT112/84 is tumorigenic in vivo, capable of forming subcutaneous tumors in nude mice. Its applications focus on investigating bladder cancer pathogenesis, particularly in the context of tumor progression, drug resistance mechanisms, and therapeutic development.
Product Code

RT112-84; RT-112/84; RT11284

Species

Human

Cat.No

ABC-TC0999

Product Category Tumor Cell Lines
Size/Quantity

1 vial

Cell Type

Epithelial

Growth Mode

Adherent

Shipping Info

Dry Ice

Growth Conditions

37 ℃, 5% CO2

Source Organ

Bladder

Biosafety Level

1

Storage

Liquid Nitrogen

Product Type

Human Bladder Cancer Cell Lines

Application

  • RT-112/84 cells offers valuable applications in cancer research, particularly in exploring cancer cell mechanisms of cancer cell invasion and metastasis. They are frequently used in tumorigenicity studies and are instrumental in evaluating the efficacy of anticancer agents. The cell line has been applied in cytotoxicity assays involving compounds such as lipoic acid and calcium hydroxycitrate, providing insights into potential therapeutic interventions. Its reproducible growth and tumor-forming capabilities make it a valuable platform for drug screening and mechanistic studies in urothelial carcinoma.

Citation

When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).

Inquiring RT-112/84

We know how valuable your research is to you, but are you wondering what you can expect to pay for quick accurate results every time? Fill out a request in the form below and we’ll get back to you within 24 hours with a quote.
High Viability
To succeed in cell culture
Precision and Reliability
To support a consistent result
Customization Options
Tailed to your research

Tags

AcceGen Scroll Top Button